Phosphodiesterase Type 5 Inhibitor–Induced Relapse of Red Scrotum Syndrome: a Model of Neurovascular Dysregulation

Clicks: 31
ID: 317658
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #48 of 247 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Red scrotum syndrome (RSS) is a rare neurovascular condition causing persistent scrotal erythema and burning pain. We report two cases of RSS relapse triggered by tadalafil, a phosphodiesterase type 5 inhibitor, used for erectile dysfunction. These observations suggest that PDE5 inhibitors may induce or exacerbate RSS through vasodilatory and neurogenic mechanisms, warranting caution in patients with a history of this condition.
Reference Key
openalex_W7165012994 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag254
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.